These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9808079)

  • 1. Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics.
    Goldstein BJ; Goodnick PJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S55-87. PubMed ID: 9808079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors.
    Peretti S; Judge R; Hindmarch I
    Acta Psychiatr Scand Suppl; 2000; 403():17-25. PubMed ID: 11019931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the use of SSRIs reduce medical care utilization and expenditures?
    Chung S
    J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of selective serotonin reuptake inhibitors in depression: a critical review.
    Frank L; Revicki DA; Sorensen SV; Shih YC
    CNS Drugs; 2001 Jan; 15(1):59-83. PubMed ID: 11465013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
    Anderson IM
    J Affect Disord; 2000 Apr; 58(1):19-36. PubMed ID: 10760555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology.
    Goodnick PJ; Goldstein BJ
    J Psychopharmacol; 1998; 12(3 Suppl B):S5-20. PubMed ID: 9808077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WITHDRAWN: Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
    Barbui C; Hotopf M; Freemantle N; Boynton J; Churchill R; Eccles MP; Geddes JR; Hardy R; Lewis G; Mason JM
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002791. PubMed ID: 17636706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
    Berndt ER; Bhattacharjya A; Mishol DN; Arcelus A; Lasky T
    J Ment Health Policy Econ; 2002 Mar; 5(1):3-19. PubMed ID: 12529566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine tenth anniversary update: the progress continues.
    Stokes PE; Holtz A
    Clin Ther; 1997; 19(5):1135-250. PubMed ID: 9385500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacoeconomics of venlafaxine in depression.
    Morrow TJ
    Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant selection: proceedings from a TCA/SSRI Concensus Conference.
    Mendlewicz J; Lecrubier Y
    Acta Psychiatr Scand Suppl; 2000; 403():5-8. PubMed ID: 11019929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fluoxetine: an update of its use in major depressive disorder in adults].
    Gourion D; Perrin E; Quintin P
    Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.
    Vaswani M; Linda FK; Ramesh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):85-102. PubMed ID: 12551730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview.
    Amrein R; Stabl M; Henauer S; Affolter E; Jonkanski I
    Can J Psychiatry; 1997 Dec; 42(10):1043-50. PubMed ID: 9469236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
    Carrasco JL; Sandner C
    Int J Clin Pract; 2005 Dec; 59(12):1428-34. PubMed ID: 16351675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.